BHST BIOHARVEST SCIENCES INC.

NEUTRAL Impact: 3/10 6-K
Horizon weeks Filed May 28, 2026 Processed 15d 22h ago SEC 0001723464-26-000032
Notable filing: 6-K
Latest settled — T+5d
BHST ▼ -8.72% at T+5d
NEUTRAL call ✗ call lost -8.72% · α vs SPY -8.67% · entry $3.90 → $3.56
Next anchor: T+20d in 13d
Currently $3.20 · -17.95% from $3.90 entry
Entry anchored
May 27, 03:59 PM ET
via Databento tick
T+1d
-1.03%
call -1.03% · α -1.27%
$3.86
settled 15d ago
T+5d
-8.72%
call -8.72% · α -8.67%
$3.56
settled 9d ago
T+20d
call — · α —
in 13d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

BioHarvest Sciences filed its annual meeting proxy circular on Form 6-K, setting the AGM for June 25, 2026. The filing is routine governance — director elections, auditor ratification, and executive compensation disclosure for FY2025. No material financial results, guidance, or strategic catalysts are included.

Actionable Insight

No immediate trading catalyst. Monitor the AGM on June 25 for any unexpected shareholder dissent or board-level strategic updates. The CEO transition from Sobel to Rakib was already disclosed in prior filings — this circular confirms the slate.

Key Facts

  • AGM scheduled for June 25, 2026 in Vancouver, BC.
  • Shareholders to elect Ilan Sobel, John Fiddick, and Anne Binder as Class I directors (term to 2029) and Yeheskel Levy as Class II director (term to 2027).
  • Ziv Haft (BDO) proposed for reappointment as auditor.
  • CEO transition: Ilan Sobel resigned as CEO and became director on April 29, 2026; Zaki Rakib appointed CEO on April 28, 2026.
  • 22,667,842 common shares outstanding as of May 19, 2026 record date.
  • Vivien Rakib beneficially owns 13.42% of outstanding shares.
  • No termination or change-of-control benefits for named executive officers.
  • Auditor fees for FY2025: ~$286,662 total (audit $169K, audit-related $45K, tax $17.5K, other $55K).
  • Equity incentive plan has 1,986,962 options outstanding and 1,395,717 shares available for future issuance.

Financial Impact

No material financial impact. Routine proxy filing with no earnings, guidance, or transaction.

Risk Factors

  • No material risks identified in this routine governance filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001723464-26-000032
Document: bhsc_6k.htm0001723464-26-000032
Document: bhsc_ex993.htm0001723464-26-000032
Document: 0001723464-26-000032-index-headers.html0001723464-26-000032
Document: 0001723464-26-000032-index.html0001723464-26-000032
Document: 0001723464-26-000032.txt0001723464-26-000032
8 reports for BHST
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for BHST — sortable, filterable
Type Now
May 28, 2026
15d ago
6-K
NEUTRAL ★ 3/10
$3.90 $3.56▼ −8.72%▼ −8.67%$3.20 (−17.95%)
May 14, 2026
29d ago
6-K
NEUTRAL ★ 5/10
$4.16 $3.82▼ −8.17%▼ −7.46%$3.20 (−23.08%)
May 14, 2026
29d ago
6-K
BEARISH ★ 6/10
$4.16 $3.82▲ +8.17%▲ +7.46%$3.20 (+23.08%)
May 14, 2026
29d ago
6-K
NEUTRAL ★ 3/10
$4.16 $3.82▼ −8.17%▼ −7.46%$3.20 (−23.08%)
May 12, 2026
4w ago
6-K
NEUTRAL ★ 4/10
$3.84 $3.96▲ +3.13%▲ +3.05%$3.20 (−16.67%)
May 11, 2026
4w ago
6-K
NEUTRAL ★ 2/10
$3.84 $3.96▲ +3.13%▲ +3.05%$3.20 (−16.67%)
Apr 29, 2026
6w ago
6-K
NEUTRAL ★ 3/10
$4.25 $4.21▼ −0.94%▼ −4.05%$3.20 (−24.71%)
Mar 27, 2026
11w ago
6-K
BULLISH ★ 7/10
$4.32 $4.36▲ +0.93%▼ −2.94%$3.20 (−25.93%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (48h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access